Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 18

1.

O-specific [corrected] polysaccharide conjugate vaccine-induced [corrected] antibodies prevent invasion of Shigella into Caco-2 cells and may be curative.

Chowers Y, Kirschner J, Keller N, Barshack I, Bar-Meir S, Ashkenazi S, Schneerson R, Robbins J, Passwell JH.

Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2396-401. Erratum in: Proc Natl Acad Sci U S A. 2007 May 1;104(18):7729.

3.

Shigellosis.

Niyogi SK.

J Microbiol. 2005 Apr;43(2):133-43. Review.

4.

Shigella interaction with intestinal epithelial cells determines the innate immune response in shigellosis.

Fernandez MI, Sansonetti PJ.

Int J Med Microbiol. 2003 Apr;293(1):55-67. Review.

PMID:
12755366
5.

Shigellosis: the current status of vaccine development.

Kweon MN.

Curr Opin Infect Dis. 2008 Jun;21(3):313-8. doi: 10.1097/QCO.0b013e3282f88b92. Review.

PMID:
18448978
6.

Strategies for development of potential candidate Shigella vaccines.

Lindberg AA, Pál T.

Vaccine. 1993;11(2):168-79. Review.

PMID:
8438615
7.

O-specific side-chain toxin-protein conjugates as parenteral vaccines for the prevention of shigellosis and related diseases.

Robbins JB, Chu C, Watson DC, Szu SC, Daniels EM, Lowe CU, Schneerson R.

Rev Infect Dis. 1991 Mar-Apr;13 Suppl 4:S362-5. Review.

PMID:
2047664
8.

Current aspects of Shigella pathogenesis.

Torres AG.

Rev Latinoam Microbiol. 2004 Jul-Dec;46(3-4):89-97. Review.

PMID:
17061529
9.

Live-attenuated Shigella vaccines.

Venkatesan MM, Ranallo RT.

Expert Rev Vaccines. 2006 Oct;5(5):669-86. Review.

PMID:
17181440
10.

Shigella vaccine development: prospective animal models and current status.

Kim YJ, Yeo SG, Park JH, Ko HJ.

Curr Pharm Biotechnol. 2013;14(10):903-12. Review.

PMID:
24372251
11.

Development of an auxotrophic oral live Shigella flexneri vaccine.

Lindberg AA, Kärnell A, Stocker BA, Katakura S, Sweiha H, Reinholt FP.

Vaccine. 1988 Apr;6(2):146-50. Review.

PMID:
2838986
12.

Inactivated and subunit vaccines to prevent shigellosis.

Kaminski RW, Oaks EV.

Expert Rev Vaccines. 2009 Dec;8(12):1693-704. doi: 10.1586/erv.09.127. Review.

PMID:
19943764
13.

Shigellosis in Vietnam: seroepidemiologic studies with use of lipopolysaccharide antigens in enzyme immunoassays.

Lindberg AA, Cam PD, Chan N, Phu LK, Trach DD, Lindberg G, Karlsson K, Kärnell A, Ekwall E.

Rev Infect Dis. 1991 Mar-Apr;13 Suppl 4:S231-7. Review.

PMID:
2047643
14.

Pathogenesis and immunology in shigellosis: applications for vaccine development.

Hale TL, Keren DF.

Curr Top Microbiol Immunol. 1992;180:117-37. Review. No abstract available.

PMID:
1380415
15.

Vaccination against shigellosis: is it the path that is difficult or is it the difficult that is the path?

Phalipon A, Mulard LA, Sansonetti PJ.

Microbes Infect. 2008 Jul;10(9):1057-62. doi: 10.1016/j.micinf.2008.07.016. Review.

PMID:
18672087
16.

Progress and pitfalls in Shigella vaccine research.

Barry EM, Pasetti MF, Sztein MB, Fasano A, Kotloff KL, Levine MM.

Nat Rev Gastroenterol Hepatol. 2013 Apr;10(4):245-55. doi: 10.1038/nrgastro.2013.12. Review.

17.

Shigella infection of intestinal epithelium and circumvention of the host innate defense system.

Ashida H, Ogawa M, Mimuro H, Sasakawa C.

Curr Top Microbiol Immunol. 2009;337:231-55. doi: 10.1007/978-3-642-01846-6_8. Review.

PMID:
19812985
18.

Pathogenesis, genetics of virulence, and immunity in Shigellosis.

Formal SB, Kapfer C, Hale TL.

Kansenshogaku Zasshi. 1988 Mar;62 Suppl:329-42. Review. No abstract available.

PMID:
3138359
Items per page

Supplemental Content

Support Center